A collection of links for all of the past CP Links in one spot.
Over the last few years, the CP Links feature has focused on providing you with the best resources on the Web related to specific childhood conditions, diseases, and developmental issues. Whether the topic is a mild derm issue such as cradle cap or a life-altering diagnoses such as leukemia, we fill each page with useful medical information from government groups, children's hospitals, or professional organizations. For easier reference, here are links to all of the past CP Links in one spot-all of them are housed on our Web portal, http://ModernMedicine.com/.
Allergy info http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=534141
Asthma info http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=501519
Breastfeeding info http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=421812
Child ADHD info http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=515818
Childhood cancer resources http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=548515
Child life programs http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=558619
Child life resources http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=558618
Diabetes info http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=485414
Diabetes camp info http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=485415
Down syndrome info http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=534144
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.